Summary:
Sonrai Analytics and AOA Dx have formed a strategic partnership to accelerate the development of AOA’s multi-omic liquid biopsy test for early ovarian cancer diagnosis using AI-powered analytics.
Takeaways:
- AI-Powered Biomarker Validation: Sonrai’s platform will enable the integration and analysis of multi-omic and clinical data to support biomarker validation for AOA’s diagnostic test.
- Secure, Cloud-Based Infrastructure: AOA will benefit from a secure, compliant environment to manage data, apply machine learning tools, and streamline research and regulatory processes.
- Improved Early Detection: The test targets early diagnosis of ovarian cancer in symptomatic women, aiming to improve outcomes and reduce healthcare costs.
Sonrai Analytics, a provider of AI precision medicine, and AOA Dx, an early-stage biotech company developing the first test to diagnose ovarian cancer in symptomatic women, today announced a strategic partnership to accelerate the development of AOA’s multi-omic liquid biopsy test. The partnership aims to advance the development of the diagnostic test through a multi-omic biomarker validation strategy.
Through the partnership, AOA will leverage Sonrai’s cloud-based advanced analytics platform, pharma-grade data infrastructure and bioinformatic expertise to integrate and analyze multi-modal data, including multi-omic and clinical data. The platform will support AOA in validating diagnostic biomarkers, enhancing the accuracy and clinical utility of its serum-based test for ovarian cancer. The test leverages a combination of novel gangliosides, lipids, and proteins to diagnose ovarian cancer in women experiencing vague abdominal symptoms. Diagnosing women when symptoms first occur could transform the pathway for women, and ultimately change outcomes, whilst offering significant savings to healthcare systems.
“We’re delighted to partner with AOA Dx to help advance the development of their innovative test for ovarian cancer. By applying our AI-powered analytics platform, we’re able to unlock deeper insights from complex multi-modal data, accelerating the validation of biomarkers, enabling earlier and more accurate detection,” says Prof. Darragh McArt, CEO and founder of Sonrai Analytics.
Automation and Machine Learning to Play a Role in Development Process
In addition, Sonrai will offer its bioinformatics expertise, enabling AOA to harness pre-built machine learning tools and run automated pipelines, all within a secure, cloud-native environment. The Sonrai Discovery platform will enable AOA to store and manage their clinical data in role-based environments that allow controlled access, workspace isolation, cross-functional collaboration, and real-time performance tracking, to ensure security, governance, and compliance.
“By partnering with Sonrai, we can not only integrate and manage our in-house development data but also cross-reference it with public datasets and analyze it seamlessly within one centralized environment,” says Dr Abigail McElhinny, chief scientific officer for AOA Dx. “The ability to combine and analyze multi-omic, clinical, and demographic data within one compliant platform is critical to both our research and regulatory approval process.”
Together, Sonrai and AOA are driving innovation where it’s needed most, improving outcomes for patients facing one of the most challenging cancers to diagnose early. This partnership reflects both companies’ commitment to innovation in precision medicine, turning complex data into life-saving diagnostics for women around the world.
